Evidence map›Paper›PMID 28286127›Full record

ReviewCell chemical biology2017

Hedgehog Signaling: From Basic Biology to Cancer Therapy.

Fujia Wu, Yu Zhang, Bo Sun, Andrew P McMahon, Yu Wang

Open access · bronzeAbstract readReview
In one paragraph

Review in Cell chemical biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 176 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
176citing papers in PubMed, 1 pooled it
15.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

176 citing papers in PubMed, 1 synthesis or guideline pooled it, 306 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Design of PKC-Targeting Benzolactams as Gli Inhibitors.ACS medicinal chemistry letters · 2026
    Article
  4. Article
  5. Article
  6. [Molecular cancer · 2026
    Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Synthesis and Evaluation of Aromatic A-Ring 23-Oxavitamin DInternational journal of molecular sciences · 2025
    Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Practical immunomodulatory landscape of glioblastoma multiforme (GBM) therapy.Journal of the Egyptian National Cancer Institute · 2024
    Review
  20. Article

116 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Fujia WuState Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China; University of Chinese Academy of Sciences, Beijing 100049, China.
Yu ZhangState Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China.
Bo SunState Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China.
Andrew P McMahonDepartment of Stem Cell Biology and Regenerative Medicine, Eli and Edythe Broad-CIRM Center for Regenerative Medicine and Stem Cell Research, W.M. Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
Yu WangState Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China; University of Chinese Academy of Sciences, Beijing 100049, China. Electronic address: wangyu@ioz.ac.cn.
Chinese Academy of Sciences · CNInstitute of Zoology · CNUniversity of Chinese Academy of Sciences · CNUniversity of Southern California · US

Funding

Regulation of polarity by Sonic hedgehog morphogen signalingR01NS033642 · NINDS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MCMAHON, ANDREW P. · 1995 to 2016
$5.7M
Regulation of CNS and Limb Polarity by Sonic HedgehogR37NS033642 · NINDS · HARVARD UNIVERSITY · PI MCMAHON, ANDREW P. · 2005 to 2011
$5.6M
NINDS NIH HHS R01 NS033642NINDS NIH HHS R37 NS033642
6 · The paper itself

Abstract

The Hedgehog (HH) signaling pathway was discovered originally as a key pathway in embryonic patterning and development. Since its discovery, it has become increasingly clear that the HH pathway also plays important roles in a multitude of cancers. Therefore, HH signaling has emerged as a therapeutic target of interest for cancer therapy. In this review, we provide a brief overview of HH signaling and the key molecular players involved and offer an up-to-date summary of our current knowledge of endogenous and exogenous small molecules that modulate HH signaling. We discuss experiences and lessons learned from the decades-long efforts toward the development of cancer therapies targeting the HH pathway. Challenges to develop next-generation cancer therapies are highlighted.

Indexed as

Signal TransductionAntineoplastic AgentsCiliaHedgehog ProteinsHumansKruppel-Like Transcription FactorsNeoplasmsOxysterolsPhosphatidylinositol PhosphatesSmall Molecule LibrariesSmoothened ReceptorAntineoplastic AgentsHedgehog ProteinsKruppel-Like Transcription FactorsOxysterolsphosphatidylinositol 4-phosphatePhosphatidylinositol PhosphatesSmall Molecule LibrariesSmoothened Receptorbasal cell carcinomacancer therapycholesteroldrug resistanceendogenous smoothened regulationGLIhedgehog signalingmedulloblastomasmoothenedstem cell

Identifiers

PMID28286127
PMCPMC7442121
OpenAlexW2594464065

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.